Karen Wai, MD
Ophthalmology · Stanford, CANPI 1073017208
Payments from drug & device makers
Across 54 payments — averaging $225.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$5K
- Alcon$2K
- AbbVie$2K
- Regeneron$982
- Astellas Pharma US Inc$669
- Glaukos Corporation$515
- plus $2K from 9 others
What the payments were for
- Consulting fees$4,77839%
- Grants$7006%
- Travel & lodging$2,48820%
- Food & beverage$4,22335%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 8 | $5,032 |
| Alcon | 5 | $1,616 |
| AbbVie | 4 | $1,577 |
| Regeneron | 4 | $982 |
| Astellas Pharma US Inc | 6 | $669 |
| Glaukos Corporation | 7 | $515 |
| Alimera Sciences, Inc. | 3 | $305 |
| Regeneron Healthcare Solutions, Inc. | 3 | $273 |
| Apellis Pharmaceuticals, Inc. | 2 | $246 |
| Astellas Pharma Global Development | 3 | $236 |
| Amgen | 2 | $217 |
| ANI Pharmaceuticals, Inc. | 3 | $177 |
| Genentech, Inc. | 2 | $136 |
| Biogen | 1 | $128 |
| Bausch & Lomb Americas Inc. | 1 | $80 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$4,939
- Izervay$577
- EYLEA HD$246
- Iluvien$221
- iStent inject W$216
- TEPEZZA$147
- EYLEA$127
- PURIFIED CORTROPHIN GEL$127
- OZURDEX$124
- YUTIQ$114
How this compares
$12,189 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 16 | $1,236 |
| Prednisolone Acetate | 26 | $894 |
| Ketorolac Tromethamine | 14 | $389 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 13 | $178 |
| ErythromycinErythromycin Base | 13 | $117 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Stanford
- Kuldev SinghStanford$1.5M
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.